New combo pill could shrink fatty liver and shed pounds

NCT ID NCT07466017

Ongoing Disease control Sponsor: Cascade Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS060380 for 16 more weeks. The goal is to see if the drug reduces liver fat and body weight safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS060380 (an experimental drug) plus semaglutide (a weight management drug)
What this could lead to: If it works, this could lead to a new treatment that reduces liver fat and body weight in people with MASH and obesity.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) OBESITY

Contacts and locations

Locations

Nanjing Jiangning Hospital

Nanjing, Jiangsu, 211100, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200001, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shanghai First People's Hospital

Shanghai, Shanghai Municipality, 200080, China
The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, 315010, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China
The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050031, China
The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230601, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China
The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510150, China
Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200336, China
Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.